StreetInsider.com News Articles

Wells Fargo sees psychedelics market reaching $11B by 2035

Mon, 27 Jul 2026 06:55:54 -0400

Investing.com -- Wells Fargo released a report on psychedelics treatments, forecasting the branded psychedelics category in depression could reach $11 billion by 2035.

The bank's analysis covers several companies including CMPS, DFTX, GHRS, and HELP, with Wells Fargo expressing a positive view ahead of Phase 3 data for DFTX and HELP.

Spravato, currently on the market, is generating sales that annualize at more than $2 billion. The treatment faced a slow start due to initial skepticism about clinical data and REMS requirements that mandated certified centers and two-hour patient monitoring periods. The COVID-19 pandemic also affected adoption rates.

Many ketamine clinics that previously

Wells Fargo sees psychedelics market reaching $11B by 2035

Mon, 27 Jul 2026 06:55:54 -0400

Investing.com -- Wells Fargo released a report on psychedelics treatments, forecasting the branded psychedelics category in depression could reach $11 billion by 2035.

The bank's analysis covers several companies including CMPS, DFTX, GHRS, and HELP, with Wells Fargo expressing a positive view ahead of Phase 3 data for DFTX and HELP.

Many ketamine clinics that previously

Wells Fargo sees psychedelics market reaching $11B by 2035

Mon, 27 Jul 2026 06:55:54 -0400

Investing.com -- Wells Fargo released a report on psychedelics treatments, forecasting the branded psychedelics category in depression could reach $11 billion by 2035.

The bank's analysis covers several companies including CMPS, DFTX, GHRS, and HELP, with Wells Fargo expressing a positive view ahead of Phase 3 data for DFTX and HELP.

Many ketamine clinics that previously

Wells Fargo sees psychedelics market reaching $11B by 2035

Mon, 27 Jul 2026 06:55:54 -0400

Investing.com -- Wells Fargo released a report on psychedelics treatments, forecasting the branded psychedelics category in depression could reach $11 billion by 2035.

The bank's analysis covers several companies including CMPS, DFTX, GHRS, and HELP, with Wells Fargo expressing a positive view ahead of Phase 3 data for DFTX and HELP.

Many ketamine clinics that previously

Wells Fargo Starts Definium Therapeutics Inc (DFTX) at Overweight

Mon, 27 Jul 2026 05:44:23 -0400

Wells Fargo initiates coverage on Definium Therapeutics Inc (NASDAQ: DFTX) with a Overweight rating and a price target of $68.00.

For an analyst ratings summary and ratings history on Definium Therapeutics Inc click here. For more ratings news on Definium Therapeutics Inc click here.

Shares of Definium Therapeutics Inc closed at $43.17 yesterday.

Definium Therapeutics Inc (DFTX) PT Raised to $73 at Piper Sandler Ahead For DT120

Fri, 24 Jul 2026 07:50:33 -0400

(Updated - July 24, 2026 7:50 AM EDT)

Piper Sandler analyst David Amsellem lifts the price target on Definium Therapeutics Inc (NASDAQ: DFTX) to $73.00 (from $48.00) while maintaining an Overweight rating.

The analyst commented: "Raising PT, With Thoughts On The Road Ahead For DT120; We are raising our PT on Definium to $73 from $48, and remain bullish on DFTX even with the shares up ~78% since the announcement of what in our view were highly differentiated results from the Phase III Emerge study of DT120 in major depressive disorder (MDD) (refer to our note on 6/22/26 for details). Our thinking

Definium Therapeutics Inc (DFTX) PT Raised to $73 at Piper Sandler Ahead For DT120

Fri, 24 Jul 2026 07:50:33 -0400

(Updated - July 24, 2026 7:50 AM EDT)

Piper Sandler analyst David Amsellem lifts the price target on Definium Therapeutics Inc (NASDAQ: DFTX) to $73.00 (from $48.00) while maintaining an Overweight rating.

Definium Therapeutics Announces New Employee Inducement Grants

Mon, 20 Jul 2026 16:01:00 -0400

NEW YORK--(BUSINESS WIRE)-- Definium Therapeutics, Inc. (“Definium” or the “Company”), a late-stage clinical biopharmaceutical company developing a new generation of therapeutics intended to address underlying causes of psychiatric and neurological disorders, today announced the issuance of inducement grants to two newly hired non-executive employees consisting of options to purchase an aggregate of 30,330 common shares of the Company (the "Options") with effective grant dates of July 20, 2026. The Options have an exercise price equal to the closing price of Definium’s common shares on the date of the grants, and will vest over a four-year period with

Definium Therapeutics Announces New Employee Inducement Grants

Mon, 20 Jul 2026 16:01:00 -0400

Definium Therapeutics Announces New Employee Inducement Grants

Mon, 20 Jul 2026 16:01:00 -0400

Definium Therapeutics Announces New Employee Inducement Grants

Mon, 20 Jul 2026 16:01:00 -0400

Definium Therapeutics launches GAD education program for providers

Thu, 16 Jul 2026 07:01:39 -0400

Definium Therapeutics (Nasdaq: DFTX) has launched a healthcare provider education initiative called Wired for Worry, focused on generalized anxiety disorder (GAD).

The platform provides evidence-based resources on GAD symptoms, disease burden, assessment tools, and neurobiology. It also highlights the use of the Generalized Anxiety Disorder-7 (GAD-7) screening scale to improve patient identification and outcomes.

According to the company, GAD affects approximately 26 million U.S. adults. Patients report up to 10 days of limitations in daily and occupational responsibilities per month, and the disorder is associated with increased risk of suicidal ideation and behavior. The last new drug approved for GAD treatment occurred

Definium Therapeutics Launches Wired for Worry, a Health Care Provider Initiative to Advance the Understanding of Generalized Anxiety Disorder (GAD) Patient Impact and Neurobiology

Thu, 16 Jul 2026 07:00:00 -0400

GAD affects approximately 26 million U.S. adults, and when left untreated, can cause chronic, pervasive, and debilitating symptoms1,2,3

Patients experience high rates of pharmacotherapy switching, discontinuation, and prolonged gaps in care4

Wired for WorryTM addresses the urgent need for greater understanding of GAD by equipping healthcare providers with education on its symptoms, lifelong impact, and underlying neurobiology

NEW YORK--(BUSINESS WIRE)-- Definium Therapeutics, Inc. (“Definium” or the “Company”), a late-stage clinical biopharmaceutical company developing a new generation of therapeutics intended to address underlying causes of psychiatric and neurological disorders, today announced the launch of Wired for Worry, a

Definium Therapeutics Launches Wired for Worry, a Health Care Provider Initiative to Advance the Understanding of Generalized Anxiety Disorder (GAD) Patient Impact and Neurobiology

Thu, 16 Jul 2026 07:00:00 -0400

GAD affects approximately 26 million U.S. adults, and when left untreated, can cause chronic, pervasive, and debilitating symptoms1,2,3

Patients experience high rates of pharmacotherapy switching, discontinuation, and prolonged gaps in care4

Wired for WorryTM addresses the urgent need for greater understanding of GAD by equipping healthcare providers with education on its symptoms, lifelong impact, and underlying neurobiology

Definium Therapeutics Launches Wired for Worry, a Health Care Provider Initiative to Advance the Understanding of Generalized Anxiety Disorder (GAD) Patient Impact and Neurobiology

Thu, 16 Jul 2026 07:00:00 -0400

GAD affects approximately 26 million U.S. adults, and when left untreated, can cause chronic, pervasive, and debilitating symptoms1,2,3

Patients experience high rates of pharmacotherapy switching, discontinuation, and prolonged gaps in care4

Wired for WorryTM addresses the urgent need for greater understanding of GAD by equipping healthcare providers with education on its symptoms, lifelong impact, and underlying neurobiology

Definium Therapeutics Launches Wired for Worry, a Health Care Provider Initiative to Advance the Understanding of Generalized Anxiety Disorder (GAD) Patient Impact and Neurobiology

Thu, 16 Jul 2026 07:00:00 -0400

GAD affects approximately 26 million U.S. adults, and when left untreated, can cause chronic, pervasive, and debilitating symptoms1,2,3

Patients experience high rates of pharmacotherapy switching, discontinuation, and prolonged gaps in care4

Wired for WorryTM addresses the urgent need for greater understanding of GAD by equipping healthcare providers with education on its symptoms, lifelong impact, and underlying neurobiology

New Healthcare Claims Study Published in CNS Spectrums Finds High Rates of Treatment Switching, Discontinuation, and Prolonged Gaps in Care Among Patients with Generalized Anxiety Disorder (GAD)